Chicago AI drug discovery shop Evozyne nabs $81M in bid to make new proteins
Chicago startup Evozyne has raised $81 million following a generative AI collaboration with Nvidia announced earlier this year.
The three-year-old startup is creating new proteins to use for therapeutics and carbon capture and has already partnered with Takeda. Evozyne announced in April 2022 that it would help create proteins for the Japanese pharma to potentially use in gene therapies, spanning up to four rare disease targets. But it’s also looking to develop its own programs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.